TransCode Therapeutics Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 6/6

TransCode Therapeutics har ett totalt eget kapital på $144.5M och en total skuld på $0.0 vilket ger sin skuldsättningsgrad till 0%. Dess totala tillgångar och totala skulder är $157.2M respektive $12.6M.

Viktig information

Skuldsättning i förhållande till eget kapital

US$0

Skuld

Räntetäckningsgrad	n/a
Kontanter	US$12.84m
Eget kapital	US$144.52m
Summa skulder	US$12.64m
Totala tillgångar	US$157.16m

Nya uppdateringar om finansiell hälsa

Recent updates

Seeking Alpha • Aug 15

TransCode Therapeutics reports Q2 results

TransCode Therapeutics press release (NASDAQ:RNAZ): Q2 Operating loss of $4.7M. TransCode expects that its cash of $13.4 million as of June 30, 2022, is sufficient to fund planned operations into the first quarter 2023 but not for a full 12 months from the date of its financial statements.

Seeking Alpha • Jul 11

TransCode files U.S. patent application for radiotherapy based cancer treatment

TransCode Therapeutics (NASDAQ:RNAZ) on Monday said it had filed a provisional U.S. patent application directed at using radiotherapy through nanoparticles to treat cancer. The U.S. patent application is 63/356,449 and is titled "Radiolabeled Nanoparticles and Template Directed Immunomodulation for Cancer Therapy." RNAZ said the application is directed at introducing radiotherapy into the delivery of nanoparticles carrying RNA-based agonist precursors of pattern recognition receptors. RNAZ stock +3.7% to $1.39 in aftermarket trading.

Analysartikel • Apr 01

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysartikel • Dec 15

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analys av finansiell ställning

Kortfristiga skulder: RNAZ s kortfristiga tillgångar ( $16.7M ) överstiger dess kortfristiga skulder ( $5.4M ).

Långfristiga skulder: RNAZ s kortfristiga tillgångar ( $16.7M ) överstiger dess långfristiga skulder ( $7.3M ).

Skuld till eget kapital Historik och analys

Skuldnivå: RNAZ är skuldfri.

Minska skulden: RNAZ har för närvarande inga skulder men vi kan inte jämföra med 5 år sedan eftersom vi inte har några uppgifter för den perioden.

Balansräkning

Analys av kontantbanan

För företag som i genomsnitt har gått med förlust tidigare bedömer vi om de har minst 1 års kassaflöde.

Stabil Cash Runway: RNAZ har tillräckligt med cash runway för 7 månader baserat på senast rapporterad fritt kassaflöde, men har sedan dess tagit in ytterligare kapital.

Prognos Cash Runway: RNAZ förväntas ha tillräckligt med kontanter under 7 månader baserat på fritt kassaflöde uppskattningar, men har sedan dess tagit in ytterligare kapital.

Upptäck friska företag

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/20 11:05
Aktiekurs vid dagens slut	2026/05/20 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

TransCode Therapeutics, Inc. bevakas av 1 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Emily Bodnar	H.C. Wainwright & Co.

TransCode Therapeutics Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 6/6

Viktig information

Nya uppdateringar om finansiell hälsa

TransCode Therapeutics, Inc. announced delayed annual 10-K filing

TransCode Therapeutics, Inc. announced delayed annual 10-K filing

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split to Meet the Minimum Bid Price Requirement

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Regain Compliance with Nasdaq Bid Price Requirement

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq

Recent updates

TransCode Therapeutics, Inc. Appoints Anna Moore as Chair of Scientific Advisory Board

TransCode Therapeutics, Inc. announced that it expects to receive $19.7 million in funding from Yorkville Advisors Global LP

TransCode Therapeutics, Inc. announced delayed annual 10-K filing

TransCode Therapeutics, Inc. Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

TransCode Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Announce Submission of Ind Amendment for Phase 2A Clinical Trial Withttx-Mc138

TransCode Therapeutics, Inc. Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

TransCode Therapeutics Presents Preliminary Data from Its Completed Phase 1a Study with Tx-MC138 in Metastatic Disease at ESMO

TransCode Therapeutics, Inc. announced that it expects to receive $25.00146 million in funding

TransCode Therapeutics, Inc., Annual General Meeting, Aug 29, 2025

TransCode Therapeutics, Inc. Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial

TransCode Therapeutics, Inc. Reports Further Progress on Phase 1A Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

TransCode Therapeutics, Inc. announced delayed annual 10-K filing

TransCode Therapeutics, Inc. Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial Withttx-Mc138

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $10.045 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split to Meet the Minimum Bid Price Requirement

TransCode Therapeutics, Inc. announced that it expects to receive $8 million in funding

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Regain Compliance with Nasdaq Bid Price Requirement

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Transcode Therapeutics, Inc. Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

Transcode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, A MicroRNA-Targeted Technology

TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq

TransCode Therapeutics, Inc. Announces First Patients Treated in Phase 1 Clinical Trial with First-In-Class Lead Therapeutic Candidate

TransCode Therapeutics Receives Deficiency Letters from the Listing Qualifications Department (The “Staff”) of the Nasdaq

TransCode Therapeutics, Inc. Announces Phase 1 Clinical Trial Initiation

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Intends to File a Request for a Hearing on or before May 14, 2024, in Response to Non-Compliance with the Nasdaq Listing Rule 5550(a)(2)

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.194863 million.

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million.

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces Management Changes

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with Its Lead Candidate, TTX-MC138

TransCode Therapeutics, Inc. to Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Required for Continued Listing on The Nasdaq Capital Market

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on the Nasdaq Stock Market Subject to Conditions

Transcode Therapeutics, Inc. Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Leading Therapeutic Candidate, Tx-Mc138

TransCode Therapeutics, Inc. Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate,TTX-MC138

TransCode Therapeutics, Inc. Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

TransCode Therapeutics Provides Non Compliance Update

TransCode Therapeutics Receives Delisting Determination Letter from Nasdaq Advising Not to Accept its Compliance Plan, and Denies its Request for an Extension

TransCode Therapeutics, Inc. Announces Publication of New Data Supporting Use of TTX-MC138 for Treatment of Metastatic Breast Cancer

New major risk - Shareholder dilution

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Lead Candidate, Tx-MC138, in Glioblastoma

TransCode Therapeutics Announces 1-For-20 Reverse Stock Split to Satisfy the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

TransCode Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

Transcode Therapeutics, Inc. Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

Transcode Therapeutics Announces Eind Submission to Us Fda for Planned First-In-Human Clinical Trial in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology

TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board

TransCode Therapeutics reports Q2 results

TransCode files U.S. patent application for radiotherapy based cancer treatment

Co-Founder recently bought US$55k worth of stock

TransCode Therapeutics, Inc. Acquires Option for Radiotheranostic Technology